VolitionRX Ltd
VNRX0.621USD
-0.019-2.94%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
62.58MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über VolitionRX Ltd Unternehmen
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Unternehmensinformationen
BörsenkürzelVNRX
Name des UnternehmensVolitionRX Ltd
IPO-datumFeb 06, 2015
CEODr. Jasmine Kway
Anzahl der mitarbeiter85
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 06
Addresse1489 West Warm Springs Road
StadtHENDERSON
BörseNYSE American Consolidated
LandUnited States of America
Postleitzahl89014
Telefon17024251561
Websitehttps://volition.com/
BörsenkürzelVNRX
IPO-datumFeb 06, 2015
CEODr. Jasmine Kway
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Guy Archibald Innes
Mr. Guy Archibald Innes
Independent Director
Independent Director
2.81M
+0.72%
Mr. Cameron John Reynolds
Mr. Cameron John Reynolds
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.08M
+10.62%
Dr. Jacob Vincent Micallef
Dr. Jacob Vincent Micallef
Chief Scientific Officer
Chief Scientific Officer
456.18K
-4.51%
Mr. Terig Hughes
Mr. Terig Hughes
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
362.01K
+38.17%
Dr. Salvatore Thomas Butera
Dr. Salvatore Thomas Butera
Chief Executive Officer of Volition Vet
Chief Executive Officer of Volition Vet
313.51K
-1.40%
Dr. Alan Colman, Ph.D.
Dr. Alan Colman, Ph.D.
Independent Director
Independent Director
203.55K
-10.28%
Dr. Jasmine Kway
Dr. Jasmine Kway
Chief Executive Officer of Singapore Volition
Chief Executive Officer of Singapore Volition
191.11K
+4.56%
Mr. Gael Forterre
Mr. Gael Forterre
Chief Commercial Officer
Chief Commercial Officer
159.47K
+0.29%
Mr. Nicholas Plummer
Mr. Nicholas Plummer
Group General Counsel
Group General Counsel
144.80K
-3.61%
Mr. Rodney Gerard Rootsaert
Mr. Rodney Gerard Rootsaert
Corporate Secretary
Corporate Secretary
138.29K
-2.17%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Guy Archibald Innes
Mr. Guy Archibald Innes
Independent Director
Independent Director
2.81M
+0.72%
Mr. Cameron John Reynolds
Mr. Cameron John Reynolds
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.08M
+10.62%
Dr. Jacob Vincent Micallef
Dr. Jacob Vincent Micallef
Chief Scientific Officer
Chief Scientific Officer
456.18K
-4.51%
Mr. Terig Hughes
Mr. Terig Hughes
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
362.01K
+38.17%
Dr. Salvatore Thomas Butera
Dr. Salvatore Thomas Butera
Chief Executive Officer of Volition Vet
Chief Executive Officer of Volition Vet
313.51K
-1.40%
Dr. Alan Colman, Ph.D.
Dr. Alan Colman, Ph.D.
Independent Director
Independent Director
203.55K
-10.28%
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Jul 5
Aktualisiert: Sat, Jul 5
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Cotterford Co., Ltd.
11.65%
Lagoda Investment Management, L.P.
9.89%
Armistice Capital LLC
7.97%
Innes (Guy Archibald)
2.72%
Reynolds (Cameron John)
2.02%
Other
65.74%
Aktionäre
Aktionäre
Anteil
Cotterford Co., Ltd.
11.65%
Lagoda Investment Management, L.P.
9.89%
Armistice Capital LLC
7.97%
Innes (Guy Archibald)
2.72%
Reynolds (Cameron John)
2.02%
Other
65.74%
Aktionärstypen
Aktionäre
Anteil
Corporation
12.63%
Investment Advisor
11.32%
Hedge Fund
8.01%
Individual Investor
7.32%
Investment Advisor/Hedge Fund
1.09%
Research Firm
0.04%
Venture Capital
0.03%
Other
59.56%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
78
41.39M
40.17%
+893.35K
2025Q1
83
44.42M
46.85%
+2.70M
2024Q4
82
41.53M
44.82%
+1.50M
2024Q3
82
38.59M
41.90%
+9.42M
2024Q2
82
28.77M
32.86%
+105.49K
2024Q1
84
28.22M
34.52%
+1.47M
2023Q4
87
26.17M
37.10%
+183.39K
2023Q3
91
25.37M
36.48%
-477.38K
2023Q2
98
25.03M
37.36%
-1.92M
2023Q1
127
25.94M
45.68%
-639.07K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Cotterford Co., Ltd.
12.01M
11.65%
--
--
Apr 25, 2025
Lagoda Investment Management, L.P.
10.19M
9.89%
+2.62M
+34.56%
Mar 31, 2025
Armistice Capital LLC
8.21M
7.97%
-275.46K
-3.25%
Mar 31, 2025
Innes (Guy Archibald)
2.81M
2.72%
+20.00K
+0.72%
Jun 03, 2025
Reynolds (Cameron John)
1.88M
1.83%
+12.50K
+0.67%
Jun 12, 2025
Concord International Inc.
1.01M
0.98%
--
--
Apr 25, 2025
Geode Capital Management, L.L.C.
761.95K
0.74%
+18.11K
+2.43%
Mar 31, 2025
The Vanguard Group, Inc.
706.06K
0.69%
+69.39K
+10.90%
Mar 31, 2025
Micallef (Jacob Vincent)
456.18K
0.44%
-21.53K
-4.51%
Jun 01, 2025
BlackRock Institutional Trust Company, N.A.
445.19K
0.43%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
